Researchers identified over 8,000 causal relationships between diseases using scientific literature and real-world patient ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

New robotic technology has arrived at Puyallup’s MultiCare Good Samaritan Hospital – and it creates a world of difference for lung cancer patients in Pierce County. The DaVinci ION robotic surgery ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

Assessment of survival benefit with immunotherapy in combination with adjuvant chemoradiation in pathologic stage II-IIIB non-small cell lung cancer.

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA ... patients with previous or current evidence of interstitial lung disease (ILD) were excluded. An Eastern ...

Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...